 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...105106107108109110111112113114115...235236» |
- | Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche
New P2 trial: A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) (clinicaltrials.gov) - Jan 27, 2022
P2, N=30, Not yet recruiting, Sponsor: Sun Yat-sen University
- || Clinical, Journal, Circulating tumor DNA: ctDNA in neuroendocrine carcinoma of gastroenteropancreatic origin or of unknown primary: the CIRCAN-NEC pilot study. (Pubmed Central) - Jan 27, 2022
This pilot study shows a high sensitivity of ctDNA assessment, which is encouraging for the future management of GEPNEC (tumour molecular diagnosis and evaluation of disease progression).
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. (Pubmed Central) - Jan 27, 2022
Three cohorts of patients were included: a discovery cohort receiving FOLFOX ± bevacizumab (BEV) (n = 146), a validation cohort receiving FOLFOXIRI + BEV (n = 230), and a control cohort receiving FOLFIRI + BEV (n = 228)...These findings were not observed in the control cohort. Thus, MS4A12 and CDX2 SNPs may have utility as predictive biomarkers of response to oxaliplatin-based treatment in mCRC patients.
- ||| HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
Clinical, P3 data, Journal: A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. (Pubmed Central) - Jan 27, 2022
P3
Thus, MS4A12 and CDX2 SNPs may have utility as predictive biomarkers of response to oxaliplatin-based treatment in mCRC patients. Algenpantucel-L immunotherapy did not improve survival in patients with borderline resectable or locally advanced unresectable PDAC receiving SOC neoadjuvant chemotherapy and chemoradiation.
- || Avastin (bevacizumab) / Roche
Clinical, P2 data, Journal: Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. (Pubmed Central) - Jan 27, 2022
P2/3
Bevacizumab was added to the first 3 (CAPOX) or 4 (FOLFOX/FOLFIRI) neoadjuvant cycles...In this randomized phase 2 trial in patients diagnosed with resectable CPM, perioperative systemic therapy seemed feasible, safe, and able to induce response of CPM, justifying a phase 3 trial. ClinicalTrials.gov Identifier: NCT02758951.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. (Pubmed Central) - Jan 27, 2022
ClinicalTrials.gov Identifier: NCT02758951. Although a doublet-EGFRi remains the recommended upfront regimen in patients with left-sided RAS and BRAF wild-type mCRC, our real life data suggest a triplet-bevacizumab might be at least equally active and effective in properly selected cases.
- || Avastin (bevacizumab) / Roche
Clinical, Review, Journal: Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review. (Pubmed Central) - Jan 27, 2022
After failure of multi-line therapy including etoposide plus cisplatin as the first-line therapy, surufatinib plus toripalimab as the second-line therapy, FOLFIRI combined with bevacizumab as the third-line therapy, he received three cycles of albumin paclitaxel plus carboplatin combined with sintilimab as the fourth-line therapy and still obtained partial response of good efficiency...This is the first case report that the albumin paclitaxel plus carboplatin combined with sintilimab has achieved good efficacy after failure of multi-line treatment of cardia NEC. It is very necessary to further explore the effectiveness and safety of this regimen in the treatment of NEC.
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Retrospective data, Review, Journal: Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. (Pubmed Central) - Jan 27, 2022
Occurrence of febrile neutropenia was significantly higher in FOLFIRINOX at both ethnic subgroups; however, that of peripheral neuropathy was significantly higher only in GNP of the Asian subgroup. Therefore, pharmacoethnicity might be a factor worth considering when deciding on a frontline chemotherapeutic regimen although the overall survival was not significantly different between FOLFIRINOX and GNP for metastatic PCs.
- | methotrexate IV / Generic mfg., methotrexate / Generic mfg.
Journal: Simultaneous determination of folate and methotrexate metabolites in serum by LC-MS/MS during high-dose methotrexate therapy. (Pubmed Central) - Jan 27, 2022
MTX is given at lethal doses and then is followed by rescue treatment with folinic acid (FA)...This notion, together with the test results in the 6 pilot patients, shows the feasibility of this method to study MTX and FA pharmacokinetics during HDMTX treatment. The method has the potential to optimize HDMTX and FA rescue treatment in individual patients.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer. (Pubmed Central) - Jan 27, 2022
However, after acquiring cetuximab resistance with gradual exposure for more than 6 months, AREG neither increased colony formation nor activated AKT and ERK after cetuximab treatment. Our results suggest that plasma AREG is a potential biomarker to predict clinical outcomes after cetuximab-based chemotherapy.
- || TRK-950 / Toray
Trial completion date, Trial primary completion date: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 27, 2022
P1b, N=181, Recruiting, Sponsor: Toray Industries, Inc
Our results suggest that plasma AREG is a potential biomarker to predict clinical outcomes after cetuximab-based chemotherapy. Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2023 --> Aug 2024
- || misetionamide (GP-2250) / Panavance Therap
Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine (clinicaltrials.gov) - Jan 27, 2022
P1, N=64, Recruiting, Sponsor: Geistlich Pharma AG
Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2023 --> Aug 2024 Phase classification: P1/2 --> P1 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | New P1/2 trial, Metastases: MEFOX: D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 27, 2022
P1/2, N=18, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- | mitomycin / Generic mfg., cisplatin / Generic mfg.
Journal: The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. (Pubmed Central) - Jan 26, 2022
Such prognostic advantage was associated with oxaliplatin plus fluorouracil-leucovorin (HR, 0.42; 95% CI, 0.19-0.93; P = .03) and cisplatin plus mitomycin (HR, 0.57; 95% CI, 0.42-0.78; P = .001) schedules. In this cohort study, HIPEC was associated with better overall survival when performed after CRS in PMP, generally without adverse effects on surgical outcomes.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: A Case of Gastric Cancer Treated with Resection and Adjuvant Chemotherapy in Japan after FOLFOX Neoadjuvant Chemotherapy in USA (Pubmed Central) - Jan 26, 2022
The guidelines in Japan do not recommend NAC. Given that Grade 2 therapeutic effect was obtained even with 1 course of the treatment, FOLFOX therapy could be effective as preoperative chemotherapy for advanced gastric cancer cases.
- || Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche
Clinical, Journal: A Case of Jejunal Perforation by Ramucirumab Just below the Treitz Ligament Treated with Primary Suture (Pubmed Central) - Jan 26, 2022
As adjuvant chemotherapy, the patient received 3 courses of CapeOX plus bevacizumab(BEV)and 20 courses of FOLFOX plus BEV and was in PR...The postoperative course was uneventful, and the patient was discharged on POD 18. Currently, RAM has been discontinued and chemotherapy is being continued with FOLFIRI.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Clinical, Journal: A Resected Case of Advanced Lower Rectal Cancer with Neoadjuvant Chemotherapy by FOLFOXIRI plus Cetuximab (Pubmed Central) - Jan 26, 2022
The postoperative course was good and the patient was discharged on postoperative day 15. The patient received 8 courses of adjuvant chemotherapy with mFOLFOX6 from the 7th postoperative week and is alive and recurrence-free 6 months after surgery.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: A Case of Resection of Para-Aortic Lymph Node Recurrence following Rectal Cancer Surgery (Pubmed Central) - Jan 26, 2022
After 6 courses of bevacizumab-FOLFIRI therapy was administered, PALN dissection was performed...The patient has been followed up for 7 years and 8 months after the first surgery, 5 years and 9 months after the curative resection, with no recurrence showed complete cure. Multidisciplinary treatment with anticancer drug and R0 resection was an effective treatment for isolated PALN recurrence of rectal cancer.
- || Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal: A Case of Advanced Esophageal Cancer Discovered Due to Suffocation, Which Was Invasive to the Trachea and Internal Carotid Artery and Treated by Chemotherapy (Pubmed Central) - Jan 26, 2022
Airway management is difficult to perform in patients with a poor response to chemotherapy due to obstruction by a tumor. On the other hand, excessive response to chemotherapy is also associated with a risk of massive hemorrhage due to arterial perforation, as observed in this case.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: A Case of Multiple Hepatic Metastases after Surgery for Low Differentiated Mucous Cancer of Sigmoid Colon with Notable Mesenteric Infiltration in Which Chemotherapy Was Effective (Pubmed Central) - Jan 26, 2022
CT evaluation 24 months postoperatively showed a complete response radiographically. This case of mucinous adenocarcinoma of the colon, in which chemotherapy was successful and long-term survival of 5 years and 2 months was achieved postoperatively, is reported together with a discussion of the literature.
- | leucovorin calcium / Generic mfg.
Preclinical, Journal: Folinic Acid Potentiates the Liver Regeneration Process after Selective Portal Vein Ligation in Rats. (Pubmed Central) - Jan 26, 2022
Finally, FA also improved liver function. In conclusion, FA has boosted liver regeneration assessed by FLR%, nuclear area size and restoration of liver function after PVL.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: TYMS 3'-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients. (Pubmed Central) - Jan 26, 2022
We also found that PDAC patients carrying the GSTP1 rs1695 GG genotype had a decreased risk for grade 3-4 hematological toxicity as compared to those with the AA or AG genotypes (p = 0.032 and p = 0.014, CDM and RM, respectively). Due to relatively high p-values, we consider that the impact of GSTP1 rs1695 requires further investigation in a larger sample size.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Retrospective data, Journal: Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer (Pubmed Central) - Jan 26, 2022
The number of metastatic tumor and portal vein invasion are key factors that affect the outcomes of conversion therapy for initially unresectable CRLM. If a patient can tolerate chemotherapy, a combination program of three-drug and targeted therapy is preferred for the active conversion therapy.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. (Pubmed Central) - Jan 26, 2022
P3
This is the first head-to-head trial showing that single-agent irinotecan yielded PFS, OS, and ORR similar to FOLFIRI, with a more favorable toxicity profile; therefore, it might be a more favorable standard chemotherapy regimen for mCRC patients who failed first-line XELOX/FOLFOX regimens. This study is registered with ClinicalTrials.gov, number NCT02935764, registered 17 October 2016, https://clinicaltrials.gov/ct2/show/NCT02935764.
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Journal, Combination therapy: Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers. (Pubmed Central) - Jan 26, 2022
FOLFnal-IRI demonstrated promising antitumor potential with an acceptable safety profile as a subsequent therapy regimen in advanced biliary tract malignancies. Further randomized controlled trials of its value as a treatment option for BTC appear justified.
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical data, Journal: Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. (Pubmed Central) - Jan 26, 2022
GN-treated patients were older and more likely to be hospitalized while on treatment. Further study evaluating comparative effectiveness between these two regimens is warranted.
- | capecitabine / Generic mfg., gemcitabine / Generic mfg.
Journal: Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy. (Pubmed Central) - Jan 26, 2022
Cox proportional hazards analysis also demonstrated that the CAPE group had superior OS compared to the GEM group in unadjusted (HR =0.13; 95% CI: 0.04-0.40) and adjusted models (HR =0.13, 95% CI: 0.03-0.52). For neoadjuvant 3WCRT, this hypothesis-generating study suggests concurrent CAPE may be a more effective radiosensitizer than GEM for patients with (B)RPC.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: Dynamics of neutrophil-to-lymphocyte ratio predict outcomes of metastatic colorectal carcinoma patients treated by FOLFOX. (Pubmed Central) - Jan 26, 2022
Patients with changes from low pre-treatment NLR to high post-treatment NLR had worse OS and PFS than that of NLR changes from high to low. It is not the NLR but the changes of NLR that may predict the efficacy of FOLFOX treatment in mCRC patients.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Effects of recombinant human adenovirus type 5 combined with transarterial chemoembolization on postoperative metastasis and recurrence of hepatocellular carcinoma patients. (Pubmed Central) - Jan 26, 2022
There were no significant differences in the incidences of adverse reactions between the rhAd5 group and control group (P>0.05). The combination of FOLFOX and rhAd5 after surgery can significantly inhibit the occurrence of metastasis and recurrence of HCC patients, improve progression free survival, and has certain safety.
- | oxaliplatin / Generic mfg., docetaxel / Generic mfg.
Journal: Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol. (Pubmed Central) - Jan 26, 2022
Four cycles of FLOT will be administered post-surgery. Primary outcome is safety and feasibility, assessed by perioperative morbidity and possible interruptions of the standard multimodal treatment pathway.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: A Novel Scoring System in Predicting Prognosis After Adjuvant FOLFOX Chemotherapy in Gastric Cancer. (Pubmed Central) - Jan 26, 2022
High PNI-NLR scores can independently affect worse prognosis of GC. Thus, it can be utilized to differentiate low risk from high risk subjects.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Trial completion date, Trial primary completion date, IO biomarker: HNGC-004: Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma (clinicaltrials.gov) - Jan 26, 2022
P2, N=60, Active, not recruiting, Sponsor: Henan Cancer Hospital
Thus, it can be utilized to differentiate low risk from high risk subjects. Completed --> Active, not recruiting | Trial completion date: Feb 2021 --> May 2024 | Trial primary completion date: Jun 2020 --> May 2021
- | Trial completion date: IDEA: Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer (clinicaltrials.gov) - Jan 25, 2022
P3, N=2000, Active, not recruiting, Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Completed --> Active, not recruiting | Trial completion date: Feb 2021 --> May 2024 | Trial primary completion date: Jun 2020 --> May 2021 Trial completion date: Sep 2017 --> Mar 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: My mom had mild avidity in her lesions on the diagnostic CT. Original plan was for PRRT as first-line on 52% KI-67 Well-diff NET. Re-biopsy showed mixed acinar-NEC (poor-diff, 80% KI-67). Not sure if PRRT will still be in the gameplan but certainly wasn't first-line (FOLFOX). (Twitter) - Jan 25, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Circulating tumor DNA: I use it fairly frequently in the under 75 mCRC. I have a patient currently who had a liver full of tumor and VAF went from 67% to 0.4% after 3 mo/6 cycles FOLFOXIRI with bev. Will be writing up case report and want to know of data on survival if ctDNA clears. (Twitter) - Jan 24, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
So, this means that…people agreed to disagree? #GI22 online Debate on FOLFOXIRI (modified or not) or not to FOLFOXIRI can resume at #ASCO22 https://t.co/08uErJKKbf (Twitter) - Jan 24, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Listen up! 🔊 This podcast from @oncologytube features Richard Dunne, M.D., discussing a @WilmotCancer Phase II study evaluating FOLFOX prior to CROSS in Stage 2/3 esophageal #cancer. #URochesterResearch @DrR_DUNNE https://t.co/w1dEA9Trhg (Twitter) - Jan 24, 2022
- | Stivarga (regorafenib) / Bayer
Trial completion date, Combination therapy, Metastases: FOLFIRINOX-R: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer (clinicaltrials.gov) - Jan 24, 2022
P1/2, N=87, Recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Trial completion date: Sep 2017 --> Mar 2022 Trial completion date: Mar 2022 --> Mar 2025
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
As someone a few FOLFOX treatments in I thank you for these jumping off points. (Twitter) - Jan 23, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
I didn’t vote, because I don’t give chemo. Although, I do encounter some resistance to giving FOLFOXIRI. (Twitter) - Jan 23, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Circulating tumor DNA: I met the caregiver of a MSI-H rectal cancer patient, who was worried her husband wasn't tolerating FOLFOX & didn't want to continue tx I felt that my mission was to tell her all about IO in MSIH rectal cancer Now he's on IO, getting tx he is able to tolerate & ctDNA -ve #GI22 (Twitter) - Jan 22, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Many doctors only give 8 cycles of FOLFOX to stage 4 #CRC patients, while others give a LOT.. So much non-uniformity of care all over the US.. #GI22 #CRCSM @ASCO (Twitter) - Jan 22, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
I agree. I do triplet in those who are fit for it. FOLFOXIRI is essentially mFOLFIRINOX but I agree with the 2400 mg/m2 5-FU dose. (Twitter) - Jan 22, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Agree w/ @doctorC369 , I use FOLFIRINOX for first line when I want to downstage tumor. and that is the chemo backbone of choice in my IIT as well https://t.co/5oR1wxeU33 (Twitter) - Jan 22, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: I use FOLFIRINOX because TRIBE & Tribe2 patients actually got 75% dose of 5-FU which is essentially FOLFIRINOX . Please let me know your thoughts.@ChiaraCrem1 @pashtoonkasi @anup_kasi @aparna1024 @VanMorrisMD @IbrahimSahinMD1 @drjasonstarr (Twitter) - Jan 22, 2022
- ||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
I don’t go beyond 4-6 cycles (3m) for oxaliplatin in metastatic setting, & then put it in my back pocket. Even in the intensive triplet FOLFOXIRI instances, can continue the doublet➕biologic, but hold the oxaliplatin. Can rechallenge later. ✅Avoid neuropathy/reactions. #GI22 (Twitter) - Jan 22, 2022
- ||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Good summary by @gabe_a_brooks about when to use and when not to use oxaliplatin. In adjuvant space, we are now used to talking 3m or 6m of FOLFOX/CAPOX but in reality, there are spaces where “aiming for 6m of therapy with low threshold to drop oxali” fits well. #GI22 (Twitter) - Jan 22, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: IDEA/ACCESS analysis by Dr. Gallois. Of pts treated with 6m of oxali-based adj chemo. Who stopped tx early (~20%)? Female, >65, PS >1, low BMI, and CAPOX > FOLFOX. DFS & OS differences seen in those who stopped ALL tx early. But no diff for those who stopped oxali early. #GI22 (Twitter) - Jan 22, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: G1018 / RESPECT by Dr. Hamaguchi: FOLFOX/CAPOX + bev vs 5-FU/cape + bev in elderly 1L mCRC. 50% of pts >80. Adding oxali did not prolong PFS or OS. Maybe in RAS wt? Difference in G2-4 neuropathy was 57% vs 15%. #GI22 (Twitter) - Jan 22, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
P2 data: CheckMate 9X8 by Dr. Lenz: Phase II FOLFOX-bev +/- nivo 1L mCRC. Median PFS 11.9 both arms (HR 0.81, p=0.3). OS HR 1.03. Did not meet endpoint to expand to P3. MSI-H not on forest plot. RAS status…? HR not given for MSS group. CD8 arm interesting. #GI22 (Twitter) - Jan 22, 2022